Sulzbach, Germany

Armin Bauer

USPTO Granted Patents = 9 


 

Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 68(Granted Patents)


Location History:

  • Sulzbach/Ts, DE (2008)
  • Sulzbach, DE (2005 - 2011)
  • Frankfurt-am-Main, DE (2004 - 2013)

Company Filing History:


Years Active: 2004-2013

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Armin Bauer: Innovator in Medicinal Chemistry

Introduction

Armin Bauer is a distinguished inventor based in Sulzbach, Germany. He has made significant contributions to the field of medicinal chemistry, holding a total of nine patents. His work primarily focuses on developing innovative compounds that have therapeutic applications.

Latest Patents

Among his latest patents is the invention of spirocyclic nitriles as protease inhibitors. This invention relates to substituted carbo- and heterocyclic spiro compounds that inhibit thiol proteases, along with processes for their preparation and their use as medicaments. Another notable patent involves heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors. This invention presents compounds that exhibit a strong antithrombotic effect, making them suitable for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses.

Career Highlights

Armin Bauer has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis Deutschland GmbH and Aventis Pharma Deutschland GmbH. His experience in these organizations has allowed him to contribute to the development of groundbreaking medical solutions.

Collaborations

Throughout his career, Armin has collaborated with notable professionals in the field, including Michael Wagner and Marc Nazare. These collaborations have further enriched his work and expanded the impact of his inventions.

Conclusion

Armin Bauer's innovative contributions to medicinal chemistry and his extensive patent portfolio highlight his role as a leading inventor in the industry. His work continues to influence the development of new therapeutic agents that address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…